Title: In vitro evaluation of 225Ac-DOTA-Substance P for targeted alpha therapy of glioblastoma multiforme
Authors: MAJKOWSKA PILIP AGNIESZKARIUS MONTRAVETA MARIABRUCHERTSEIFER FRANKAPOSTOLIDIS CHRISTOSWEIS MIRJAMBONELLI MILTONLAURENZA MARTAKROLICKI LESZEKMORGENSTERN ALFRED
Citation: CHEMICAL BIOLOGY & DRUG DESIGN vol. 92 no. 1 p. 1344-1356
Publisher: WILEY-BLACKWELL
Publication Year: 2018
JRC N°: JRC109759
ISSN: 1747-0277
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC109759
DOI: 10.1111/cbdd.13199
Type: Articles in periodicals and books
Abstract: Glioblastoma multiforme (GBM) is the most malignant form of brain tumors with dismal prognosis despite treatment by surgery combined with radiotherapy and chemotherapy. The neuropeptide Substance P (SP) is the physiological ligand of the neurokinin‐1 receptor, which is highly expressed in glioblastoma cells. Thus, SP represents a potential ligand for targeted alpha therapy. In this study, a protocol for the synthesis of SP labeled with the alpha emitter 225Ac was developed and binding affinity properties were determined. The effects of 225Ac‐DOTA‐SP were investigated on human glioblastoma cell lines (T98G, U87MG, U138MG) as well as GBM stem cells. A significant dose‐dependent reduction in cell viability was detected up to 6 days after treatment. Also, colony‐forming capacity was inhibited at the lower doses tested. In comparison, treatment with the conventional agent temozolomide showed higher cell viability and colony‐forming capacity. 225Ac‐DOTA‐SP treatment caused induction of late apoptosis pathways. Cells were arrested to G2/M‐phase upon treatment. Increasing doses and treatment time caused additional S‐phase arrest. Similar results were obtained using human glioblastoma stem cells, known to show radioresistance. Our data suggest that 225Ac‐DOTA‐SP is a promising compound for treatment of GBM.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.